DCF Advisers, LLC - Q4 2022 holdings

$148 Million is the total value of DCF Advisers, LLC's 67 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .

 Value Shares↓ Weighting
ARGX  ARGENX SEsponsored adr$9,470,750
+7.3%
25,0000.0%6.40%
+12.3%
INCY  INCYTE CORP$3,534,080
+20.5%
44,0000.0%2.39%
+26.1%
IAU  ISHARES GOLD TRishares new$3,459,000
+9.7%
100,0000.0%2.34%
+14.8%
LLY  LILLY ELI & CO$3,018,180
+13.1%
8,2500.0%2.04%
+18.3%
AOD  ABERDEEN TOTAL DYNAMIC DIVD$2,121,600
+9.2%
272,0000.0%1.43%
+14.3%
AMD  ADVANCED MICRO DEVICES INC$1,943,100
+2.2%
30,0000.0%1.31%
+6.9%
PFE  PFIZER INC$1,857,450
+17.1%
36,2500.0%1.26%
+22.4%
GM  GENERAL MTRS CO$1,480,160
+4.8%
44,0000.0%1.00%
+9.6%
F  FORD MTR CO DEL$988,550
+3.8%
85,0000.0%0.67%
+8.6%
CSCO  CISCO SYS INC$952,800
+19.1%
20,0000.0%0.64%
+24.6%
QCOM  QUALCOMM INC$824,550
-2.7%
7,5000.0%0.56%
+1.8%
BIF  SRH TOTAL RETURN FUND INC$749,300
+16.7%
59,0000.0%0.51%
+21.9%
NOK  NOKIA CORPsponsored adr$696,000
+8.6%
150,0000.0%0.47%
+13.5%
ALNY  ALNYLAM PHARMACEUTICALS INC$332,710
+18.8%
1,4000.0%0.22%
+24.3%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-02-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTRA-CELLULAR THERAPIES INC16Q3 202310.2%
MICRON TECHNOLOGY INC16Q3 20236.7%
ALPHABET INC16Q3 20235.8%
ABBVIE INC16Q3 20237.9%
REGENERON PHARMACEUTICALS16Q3 20235.5%
ARGENX SE16Q3 20236.4%
SPDR GOLD TRUST16Q3 20236.6%
XENCOR INC16Q3 20234.1%
BK OF AMERICA CORP16Q3 20235.4%
ORACLE CORP16Q3 20233.2%

View DCF Advisers, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-09
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-11
13F-HR2022-05-13
13F-HR2022-02-10
13F-HR2021-11-15

View DCF Advisers, LLC's complete filings history.

Compare quarters

Export DCF Advisers, LLC's holdings